Boston Financial Mangement Inc Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Boston Financial Mangement Inc reduced its stake in Pfizer by 25.05% during the most recent quarter end. The investment management company now holds a total of 1,531,525 shares of Pfizer which is valued at $51,428,610 after selling 511,815 shares in Pfizer , the firm said in a disclosure report filed with the SEC on May 3, 2016.Pfizer makes up approximately 7.67% of Boston Financial Mangement Inc’s portfolio.

Other Hedge Funds, Including , Richard Bernstein Advisors reduced its stake in PFE by selling 223,675 shares or 78.51% in the most recent quarter. The Hedge Fund company now holds 61,213 shares of PFE which is valued at $2,055,533. Pfizer makes up approx 0.20% of Richard Bernstein Advisors’s portfolio.Old Second National Bank Of Aurora reduced its stake in PFE by selling 9,844 shares or 35.31% in the most recent quarter. The Hedge Fund company now holds 18,036 shares of PFE which is valued at $600,058. Pfizer makes up approx 0.28% of Old Second National Bank Of Aurora’s portfolio.Wendell David Associates Inc reduced its stake in PFE by selling 1,688 shares or 2.84% in the most recent quarter. The Hedge Fund company now holds 57,817 shares of PFE which is valued at $1,923,572. Pfizer makes up approx 0.37% of Wendell David Associates Inc’s portfolio.

Pfizer closed down -0.02 points or -0.06% at $33.8 with 2,47,87,046 shares getting traded on Tuesday. Post opening the session at $33.83, the shares hit an intraday low of $33.48 and an intraday high of $33.87 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Many Wall Street Analysts have commented on Pfizer. Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.